抗うつ剤の世界市場レポート 2025年

抗うつ剤の市場規模は、今後数年間で安定した成長が見込まれます。2029年にはCAGR3.2％で202億5,000万米ドルに成長します。予測期間の成長は、メンタルヘルスに対する意識の高まりと擁護、ストレスとライフスタイルの変化による世界の影響、メンタルヘルスサービスの統合、精神医学の研究開発、遠隔医療、遠隔メンタルヘルスサービスなどに起因すると考えられます。予測期間における主な動向としては、規制の変更、市場競争、ジェネリック市場の成長、副作用プロファイルの重視、新興市場などが挙げられます。

精神疾患の世界の急増は、抗うつ薬産業の拡大に寄与する極めて重要な要因であり、相当数の個人がうつ病、不安障害、様々な精神疾患などの症状に対処するためにこれらの薬に依存しています。抗うつ薬は、強迫性障害、小児尿崩症、大うつ病性障害、重度不安障害、双極性障害、心的外傷後ストレス障害（PTSD）、社会不安障害など、さまざまな疾患の治療に応用されています。世界のうつ病の有病率は2％から6％で、高齢者は他の年齢層に比べてリスクが高いです。世界保健機関（WHO）によると、2023年には世界で約2億8,000万人がうつ病に罹患しており、抗うつ薬市場の原動力として精神疾患の症例が増加していることが強調されています。

精神疾患の有病率の上昇は、将来的に抗うつ剤市場の需要を促進すると予想されます。精神疾患は、個人の考え方、感じ方、行動、信念に影響を与える障害であり、多くの場合、社会的、職場的、家族的環境での機能における苦痛や課題から生じる。抗うつ剤は、うつ病、不安障害、気分障害など、さまざまなメンタルヘルス問題の治療に用いられる薬です。これらの薬は、気分や感情を制御する脳内の特定の化学物質の濃度を高めることによって機能します。例えば、2022年11月、英国の政府機関である国民保健サービス（National Health Service）は、17歳から19歳の精神障害の有病率は、2021年の6人に1人（17.4％）から2022年には4人に1人（25.7％）に上昇したと報告しました。このように、精神疾患の罹患率の増加は、抗うつ剤市場を推進することになります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界抗うつ剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の抗うつ剤市場：成長率分析
• 世界の抗うつ剤市場の実績：規模と成長, 2019-2024
• 世界の抗うつ剤市場の予測：規模と成長, 2024-2029, 2034F
• 世界抗うつ剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の抗うつ剤市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 選択的セロトニン再取り込み阻害薬（SSRI）
• セロトニン・ノルエピネフリン再取り込み阻害剤（SNRI）
• 三環系抗うつ薬（TCA）
• モノアミン酸化酵素阻害剤（MAOI）
• 世界の抗うつ剤市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノアミン酸化酵素阻害剤
• セロトニン拮抗薬および再取り込み阻害剤
• セロトニン・ノルエピネフリン再取り込み阻害剤
• 選択的セロトニン再取り込み阻害剤
• 三環式抗うつ剤
• 世界の抗うつ剤市場うつ病による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 大うつ病性障害
• 強迫性障害
• 全般性不安障害
• パニック障害
• 世界の抗うつ剤市場選択的セロトニン再取り込み阻害薬（SSRI）の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• フルオキセチン
• セルトラリン
• エスシタロプラム
• パロキセチン
• シタロプラム
• 世界の抗うつ剤市場セロトニン・ノルエピネフリン再取り込み阻害剤（SNRI）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ベンラファキシン
• デュロキセチン
• デスベンラファキシン
• 世界の抗うつ剤市場三環系抗うつ薬（TCA）の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アミトリプチリン
• ノルトリプチリン
• イミプラミン
• ドキセピン
• 世界の抗うつ剤市場モノアミン酸化酵素阻害剤（MAOI）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• フェネルジン
• トラニルシプロミン
• イソカルボキサジド

第7章 地域別・国別分析

• 世界の抗うつ剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の抗うつ剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 抗うつ剤市場：競合情勢
• 抗うつ剤市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Sanofi S.A.
• Bristol Myers Squibb Company
• Fresenius Kabi AG
• Abbott Laboratories
• AstraZeneca plc
• GlaxoSmithKline plc
• Takeda Pharmaceutical Co. Ltd.
• Eli Lilly and Company
• Boehringer Ingelheim GmbH
• H. Lundbeck AS
• Teva Pharmaceutical Industries Ltd.
• Akeda Pharmaceutical Co.
• Otsuka Pharmaceutical Co.
• Mylan N.V

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 抗うつ剤市場2029：新たな機会を提供する国
• 抗うつ剤市場2029：新たな機会を提供するセグメント
• 抗うつ剤市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Antidepressants are medications designed to alleviate depressive symptoms, and they can also be effective in addressing seasonal affective disorder (SAD), various anxiety disorders, and social anxiety disorder. However, it's important to note that unpleasant side effects may accompany the use of antidepressants. Initially, individuals may experience common signs and symptoms such as nausea, weight gain, or disruptions in sleep patterns.

The primary categories of antidepressants include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). SSRIs, a widely used medication type, are employed not only for treating depression but also for addressing certain other mental health conditions. The diverse range of drug classes encompasses monoamine oxidase inhibitors, serotonin antagonist and reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, and tricyclic antidepressants, all of which find application in treating major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, and panic disorder.

The antidepressants market research report is one of a series of new reports from The Business Research Company that provides antidepressants market statistics, including antidepressants industry global market size, regional shares, competitors with an antidepressants market share, detailed antidepressants market segments, market trends, and opportunities, and any further data you may need to thrive in the antidepressants industry. This antidepressants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The antidepressants market size has grown steadily in recent years. It will grow from $17.11 billion in 2024 to $17.82 billion in 2025 at a compound annual growth rate (CAGR) of 4.2%. The growth in the historic period can be attributed to increasing prevalence of mental health disorders, growing awareness and reduced stigma, advancements in diagnostic practices, expansion of treatment options, government initiatives and mental health policies.

The antidepressants market size is expected to see steady growth in the next few years. It will grow to $20.25 billion in 2029 at a compound annual growth rate (CAGR) of 3.2%. The growth in the forecast period can be attributed to rising mental health awareness and advocacy, global impact of stress and lifestyle changes, integration of mental health services, research and development in psychiatry, telemedicine and remote mental health services. Major trends in the forecast period include regulatory changes, market competition, generic market growth, focus on side effect profiles, emerging markets.

The global surge in mental health disorders is a pivotal factor contributing to the expansion of the antidepressant drug industry, with a considerable number of individuals relying on these medications to address conditions such as depression, anxiety disorders, and various mental illnesses. Antidepressant drugs find application in treating a spectrum of disorders, including OCD, childhood enuresis, major depressive disorder, severe anxiety disorder, bipolar disorder, post-traumatic stress disorder (PTSD), and social anxiety disorder. The prevalence of depression globally ranges from 2% to 6%, with the elderly facing a higher risk compared to other age groups. According to the World Health Organization (WHO), approximately 280 million people worldwide suffered from depression in 2023, highlighting the escalating cases of mental health disorders as a driving force for the antidepressant market.

The rising prevalence of mental illness is anticipated to drive demand for the antidepressants market in the future. Mental illnesses are disorders that affect how individuals think, feel, behave, or believe, often arising from distress or challenges in functioning within social, work, or family settings. Antidepressants are medications used to treat a range of mental health issues, including depression, anxiety, and mood disorders. They function by increasing the levels of specific chemicals in the brain that regulate mood and emotions. For example, in November 2022, the National Health Service, a UK government agency, reported that the prevalence of probable mental disorders among individuals aged 17 to 19 rose from 1 in 6 (17.4%) in 2021 to 1 in 4 (25.7%) in 2022. Thus, the growing incidence of mental illness is set to propel the antidepressants market.

A noteworthy trend in the antidepressant market is the treatment of resistant depression, with ketamine emerging as a novel therapeutic approach. Ketamine, initially used for anesthesia during surgery, stimulates glutamate development, prompting the brain to form new neural connections. This enhances the brain's adaptability and capacity to develop new pathways, aiding individuals in fostering more positive thoughts and behaviors. The Food and Drug Administration (FDA) approved esketamine, a new ketamine depression drug, in a nasal spray form for patients who have unsuccessfully tried two antidepressants before.

Major companies in the antidepressant market are strategically focusing on introducing new drugs to maximize revenue. For example, Biogen Inc and Sage Therapeutics, Inc. launched ZURZUVAE (zuranolone) in August 2023, an oral treatment for postpartum depression (PPD), addressing the underdiagnosed and undertreated condition. ZURZUVAE (zuranolone) is the first FDA-approved medication specifically designed for PPD.

In December 2023, AbbVie Inc., a pharmaceutical company based in the United States, acquired Cerevel Therapeutics Holdings, Inc. for $8.7 billion. This strategic move is intended to bolster AbbVie's ability to address complex neurological conditions and improve patient outcomes by offering enhanced therapeutic options. Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company in the U.S. that focuses on developing innovative treatments for disorders of the central nervous system (CNS).

Major companies operating in the antidepressants market include Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol Myers Squibb Company, Fresenius Kabi AG, Abbott Laboratories, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Co. Ltd., Eli Lilly and Company, Boehringer Ingelheim GmbH, H. Lundbeck AS, Teva Pharmaceutical Industries Ltd., Akeda Pharmaceutical Co., Otsuka Pharmaceutical Co., Mylan N.V, Sun Pharmaceuticals Pvt. Ltd., Servier Laboratories, Sumitomo Dainippon Pharma Co., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Allergan plc, Alkermes plc, Egis Pharmaceuticals plc, Forest Laboratories Inc.

North America was the largest region in the antidepressants market in 2024. Middle East is expected to be the largest growing region in the global antidepressants market during the forecast period. The regions covered in the antidepressants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the antidepressants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The antidepressants market consists of sales of duloxetine, desvenlafaxine, vilazodone, citalopram, and sertraline. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antidepressants Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antidepressants market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antidepressants ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antidepressants market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Selective Serotonin Reuptake Inhibitor (SSRI); Serotonin-norepinephrine Reuptake Inhibitor (SNRI); Tricyclic Antidepressant (TCA); Monoamine Oxidase Inhibitor (MAOI)
• 2) By Drug Class: Monoamine Oxidase Inhibitors; Serotonin Antagonist And Reuptake Inhibitors; Serotonin-Norepinephrine Reuptake Inhibitors; Selective Serotonin Reuptake Inhibitors; Tricyclic Antidepressants
• 3) By Depressive Disorder: Major Depressive Disorder; Obsessive-Compulsive Disorder; Generalized Anxiety Disorder; Panic Disorder
• Subsegments:
• 1) By Selective Serotonin Reuptake Inhibitor (SSRI): Fluoxetine; Sertraline; Escitalopram; Paroxetine; Citalopram
• 2) By Serotonin-norepinephrine Reuptake Inhibitor (SNRI): Venlafaxine; Duloxetine; Desvenlafaxine
• 3) By Tricyclic Antidepressant (TCA): Amitriptyline; Nortriptyline; Imipramine; Doxepin
• 4) By Monoamine Oxidase Inhibitor (MAOI): Phenelzine; Tranylcypromine; Isocarboxazid
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Antidepressants Market Characteristics

3. Antidepressants Market Trends And Strategies

4. Antidepressants Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Antidepressants Growth Analysis And Strategic Analysis Framework

• 5.1. Global Antidepressants PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Antidepressants Market Growth Rate Analysis
• 5.4. Global Antidepressants Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Antidepressants Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Antidepressants Total Addressable Market (TAM)

6. Antidepressants Market Segmentation

• 6.1. Global Antidepressants Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Selective Serotonin Reuptake Inhibitor (SSRI)
• Serotonin-norepinephrine Reuptake Inhibitor (SNRI)
• Tricyclic Antidepressant (TCA)
• Monoamine Oxidase Inhibitor (MAOI)
• 6.2. Global Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoamine Oxidase Inhibitors
• Serotonin Antagonist And Reuptake Inhibitors
• Serotonin-Norepinephrine Reuptake Inhibitors
• Selective Serotonin Reuptake Inhibitors
• Tricyclic Antidepressants
• 6.3. Global Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Major Depressive Disorder
• Obsessive-Compulsive Disorder
• Generalized Anxiety Disorder
• Panic Disorder
• 6.4. Global Antidepressants Market, Sub-Segmentation Of Selective Serotonin Reuptake Inhibitor (SSRI), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fluoxetine
• Sertraline
• Escitalopram
• Paroxetine
• Citalopram
• 6.5. Global Antidepressants Market, Sub-Segmentation Of Serotonin-norepinephrine Reuptake Inhibitor (SNRI), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Venlafaxine
• Duloxetine
• Desvenlafaxine
• 6.6. Global Antidepressants Market, Sub-Segmentation Of Tricyclic Antidepressant (TCA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Amitriptyline
• Nortriptyline
• Imipramine
• Doxepin
• 6.7. Global Antidepressants Market, Sub-Segmentation Of Monoamine Oxidase Inhibitor (MAOI), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Phenelzine
• Tranylcypromine
• Isocarboxazid

7. Antidepressants Market Regional And Country Analysis

• 7.1. Global Antidepressants Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Antidepressants Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Antidepressants Market

• 8.1. Asia-Pacific Antidepressants Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Antidepressants Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Antidepressants Market

• 9.1. China Antidepressants Market Overview
• 9.2. China Antidepressants Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Antidepressants Market

• 10.1. India Antidepressants Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Antidepressants Market

• 11.1. Japan Antidepressants Market Overview
• 11.2. Japan Antidepressants Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Antidepressants Market

• 12.1. Australia Antidepressants Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Antidepressants Market

• 13.1. Indonesia Antidepressants Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Antidepressants Market

• 14.1. South Korea Antidepressants Market Overview
• 14.2. South Korea Antidepressants Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Antidepressants Market

• 15.1. Western Europe Antidepressants Market Overview
• 15.2. Western Europe Antidepressants Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Antidepressants Market

• 16.1. UK Antidepressants Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Antidepressants Market

• 17.1. Germany Antidepressants Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Antidepressants Market

• 18.1. France Antidepressants Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Antidepressants Market

• 19.1. Italy Antidepressants Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Antidepressants Market

• 20.1. Spain Antidepressants Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Antidepressants Market

• 21.1. Eastern Europe Antidepressants Market Overview
• 21.2. Eastern Europe Antidepressants Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Antidepressants Market

• 22.1. Russia Antidepressants Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Antidepressants Market

• 23.1. North America Antidepressants Market Overview
• 23.2. North America Antidepressants Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Antidepressants Market

• 24.1. USA Antidepressants Market Overview
• 24.2. USA Antidepressants Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Antidepressants Market

• 25.1. Canada Antidepressants Market Overview
• 25.2. Canada Antidepressants Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Antidepressants Market

• 26.1. South America Antidepressants Market Overview
• 26.2. South America Antidepressants Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Antidepressants Market

• 27.1. Brazil Antidepressants Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Antidepressants Market

• 28.1. Middle East Antidepressants Market Overview
• 28.2. Middle East Antidepressants Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Antidepressants Market

• 29.1. Africa Antidepressants Market Overview
• 29.2. Africa Antidepressants Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Antidepressants Market Competitive Landscape And Company Profiles

• 30.1. Antidepressants Market Competitive Landscape
• 30.2. Antidepressants Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Antidepressants Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Sanofi S.A.
• 31.3. Bristol Myers Squibb Company
• 31.4. Fresenius Kabi AG
• 31.5. Abbott Laboratories
• 31.6. AstraZeneca plc
• 31.7. GlaxoSmithKline plc
• 31.8. Takeda Pharmaceutical Co. Ltd.
• 31.9. Eli Lilly and Company
• 31.10. Boehringer Ingelheim GmbH
• 31.11. H. Lundbeck AS
• 31.12. Teva Pharmaceutical Industries Ltd.
• 31.13. Akeda Pharmaceutical Co.
• 31.14. Otsuka Pharmaceutical Co.
• 31.15. Mylan N.V

32. Global Antidepressants Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Antidepressants Market

34. Recent Developments In The Antidepressants Market

35. Antidepressants Market High Potential Countries, Segments and Strategies

• 35.1 Antidepressants Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Antidepressants Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Antidepressants Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer